BI IO Canada Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BI IO Canada Inc.
Scorpion Nabs $108m, Biopharma Veterans For Precision Oncology 2.0
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
Boehringer’s Philosophy Of Deal-Making: A Conversation With Ioannis Sapountzis And Scott DeWire
The German pharma’s top business development execs explain how they balance IO and targeted cancer therapy in their portfolio, views on major M&A and how to make deals during a global pandemic.
Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
BI Strengthens Research Efforts In IO Stromal Biology And Retinal Disease
Two preclinical antibodies targeted at stromal biology-associated immuno-oncology processes from Canada’s Northern Biologics have been acquired by Boehringer Ingelheim, which is also to collaborate with Switzerland’s CDR-Life on the development of a preclinical antibody fragment aimed at geographic atrophy associated with age-related macular degeneration.
- Large Molecule
- Other Names / Subsidiaries
- Mosaic Bomedicals SL
- Northern Biologics Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.